Cathie Woods Slowly Accumulated Shares in Less Known Biopharmaceutical Company NRIX

Per Bloomberg

Cathie Woods' Ark Genomic Revolution ETF has been accumulating shares of a less-known biopharmaceutical company called Nurix Therapeutics Inc since October 10.

Woods started purchasing after NRIX shares dropped over 75% from its January 2021 record. The fund has accumulated 840,000 shares in the company with a market cap worth $518 million.

Ark has secured a top 15 shareholders spot in Nurix with an over 2.7% stake. The fund's medicine ETF is down 50% this year.

See full $NRIX flow at unusualwhales.com/flow.